Clinical Trial Update: Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating direct-acting antiviral therapy to prevent HCV infection in HCV-positive donor to HCV-negative recipient kidney transplants has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Renal Failure

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Renal Failure Chronic, Hepatitis C | Phase 4 | Status: WITHDRAWN